Andrea Botticelli | Ricerc@Sapienza

Pubblicazioni

Titolo	Pubblicato in	Anno
A network approach to define the predictive role of immune profile on tumor response and toxicity of anti PD-1 single agent immunotherapy in patients with solid tumors	FRONTIERS IN IMMUNOLOGY	2023
Network approach in liquidomics landscape	JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH	2023
The impact of drug–drug Interactions on the toxicity profile of combined treatment with BRAF and MEK Inhibitors in patients with BRAF-mutated metastatic melanoma	CANCERS	2023
Systemic therapy de-escalation in advanced ovarian cancer: a new era on the horizon?	INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER	2023
Surgical and survival outcomes with perioperative or neoadjuvant immune-checkpoint inhibitors combined with platinum-based chemotherapy in resectable NSCLC: A systematic review and meta-analysis of randomised clinical trials	CRITICAL REVIEWS IN ONCOLOGY/HEMATOLOGY	2023
PD-L1 testing in metastatic triple negative breast cancer: Results of an Italian survey	TUMORI	2023
Rheumatic Diseases Development in Patients Treated by Anti-PD1 Immune Checkpoint Inhibitors: A Single-Centre Descriptive Study	LIFE	2023
DARPP-32 and t-DARPP in the development of resistance to anti-HER2 agents. Pre-clinical evidence from the STEP study	NEOPLASIA	2023
Do more targets allow more cancer treatments, or not?	EUROPEAN JOURNAL OF CANCER	2023
Adjuvant capecitabine in triple negative breast cancer patients with residual disease after neoadjuvant treatment: real-world evidence from CaRe, a multicentric, observational study	FRONTIERS IN ONCOLOGY	2023
Safety of extended interval dosing immune checkpoint inhibitors. A multicenter cohort study	JOURNAL OF THE NATIONAL CANCER INSTITUTE	2023
Real-world clinical outcomes of patients with stage I HER2-positive breast cancer treated with adjuvant paclitaxel and trastuzumab	CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY	2023
Real-world ANASTASE study of atezolizumab+nab-paclitaxel as first-line treatment of PD-L1-positive metastatic triple-negative breast cancer	NPJ BREAST CANCER	2023
Immune responses and clinical outcomes following the third dose of SARS-CoV-2 mRNA-BNT162b2 vaccine in advanced breast cancer patients receiving targeted therapies: a prospective study	FRONTIERS IN ONCOLOGY	2023
Pathologic response and survival after neoadjuvant chemotherapy with or without pertuzumab in patients with HER2-positive breast cancer: the Neopearl nationwide collaborative study	FRONTIERS IN ONCOLOGY	2023
Do more targets allow more cancer treatments, or not?	EUROPEAN JOURNAL OF CANCER	2023
Immune responses and clinical outcomes following the third dose of SARS-CoV-2 mRNA-BNT162b2 vaccine in advanced breast cancer patients receiving targeted therapies: a prospective study	FRONTIERS IN ONCOLOGY	2023
Circulating CD137 + T cells correlate with improved response to anti-PD1 immunotherapy in cancer patients	CLINICAL CANCER RESEARCH	2022
Circulating immune profile can predict survival of metastatic uveal melanoma patients: results of an exploratory study	HUMAN VACCINES & IMMUNOTHERAPEUTICS	2022
Immune effects of CDK4/6 inhibitors in patients with HR+/HER2− metastatic breast cancer: relief from immunosuppression is associated with clinical response	EBIOMEDICINE	2022

Progetti di Ricerca

Window therapy with CDK 4/6 inhibitors in head and neck cancer patients treated with immunotherapy